Basic Information
-
Targeting strategy
-
Gene targeting strategy for B-hANG2 mice.
The exons 1-9 of mouse Angpt2 gene that encode the full-length protein were replaced by human ANGPT2 exons 1-9 in B-hANG2 mice.
-
Protein expression analysis
-
Strain specific ANG2 expression analysis in homozygous B-hANG2 mice by ELISA.
Plasma was collected from wild-type mice (+/+) and homozygous B-hANG2 mice (H/H), and analyzed by ELISA. Mouse ANG2 was detectable in wild-type mice. Human ANG2 was only detectable in homozygous B-hANG2 mice. ND: not detectable.
-
In vivo efficacy of anti-VEGFA and ANG2 bispecific antibody in B-hANG2 mice
-
In vivo efficacy of anti-VEGFA and ANG2 bispecific antibody in B-hANG2 mice. B-hANG2 mice which established a choroidal neovascularizations (CNVs) model by laser treatment were randomly divided into four groups (n=4/group, female, 6-7 weeks). PBS (as a control) and bispecific antibody Faricimab targeted both VEGFA and ANG2 were administered to the mice individually (ivt, various dosages). All animals underwent FFA (fundus fluorescein angiography) on Day 7 to quantify the FFA scores (ranging from Grade I to IV,) and lesion area. (A) The leakage score and leakage area of B-hANG2mice after Faricimab treatment. (B) The FFA images of B-hANG2 mice after Faricimab treatment on Day 7. Values are expressed as mean ± SEM, *P < 0.05, **P < 0.01: Faricimab (dose 1, 2, 3) vs PBS (One-Way ANOVA).
Note: All the co-validation data were provided by pharmalegacy.
